Clinical Trial

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

Study acronym: EPP
Completed Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)
Protocol Amendment History 4 changes
critical Trial status changed: Enrolling by Invitation → Completed 2026-07-30
notable Enrollment increased: 14 -> 28 participants 2026-07-30
notable Primary completion moved earlier: 2026-01-01 -> 2025-11-22 2026-07-30
minor Completion moved earlier: 2026-01 -> 2025-11-24 2026-07-30
Trial Details
NCT Number NCT06971900
Lead Sponsor Portal Therapeutics, Inc.
Collaborators: Celerion
Conditions Erythropoietic Protoporphyria (EPP)
Enrollment 28 participants
Start Date 2025-04-04
Primary Completion 2025-11-22 (estimated)
Study Completion 2025-11-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-29